FLYSYN
Alternative Names: 4G8-SDIEMLatest Information Update: 21 May 2022
At a glance
- Originator Synimmune
 - Class Antineoplastics; Immunotherapies; Monoclonal antibodies
 - Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
 
- 
          
            
              Orphan Drug Status
              No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
 - New Molecular Entity Yes
 
Highest Development Phases
- Phase I/II Acute myeloid leukaemia
 
Most Recent Events
- 08 Apr 2022 Updated efficacy data from a phase I/II trial in Acute myeloid leukaemia presented at the 113th Annual Meeting of the American Association for Cancer Research (AACR-2022)
 - 27 Sep 2021 Synimmune in collaboration with University Hospital Tubingen completes a phase Ib/IIa trial in Acute myeloid leukaemia (Monotherapy) in Germany (IV) (NCT02789254)
 - 06 Sep 2021 GenScript ProBio and Synimmune enters into manufacturing agreement for technology transfer and manufacturing of drug substance and drug product for clinical phase II trial of FLYSYN antibody